TITLE

Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8

AUTHOR(S)
Jiang, Hualin; Zhong, Fangfang; Sun, Lu; Feng, Weiyue; Huang, Zhong-Xian; Tan, Xiangshi
PUB. DATE
April 2011
SOURCE
Amino Acids;Apr2011, Vol. 40 Issue 4, p1195
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The cytochrome P450 (CYP) superfamily plays a key role in the oxidative metabolism of a wide range of drugs and exogenous chemicals. CYP2C8 is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel in the human liver. Nearly all previous works about polymorphic variants of CYP2C8 were focused on unpurified proteins, either cells or human liver microsomes; therefore their structure-function relationships were unclear. In this study, two polymorphic enzymes of CYP2C8 (CYP2C8.4 (I264M) and CYP2C8 P404A) were expressed in E. coli and purified. Metabolic activities of paclitaxel by the two purified polymorphic enzymes were observed. The activity of CYP2C8.4 was 25% and CYP2C8 P404A was 30% of that of WT CYP2C8, respectively. Their structure-function relationships were systematically investigated for the first time. Paclitaxel binding ability of CYP2C8.4 increased about two times while CYP2C8 P404A decreased about two times than that of WT CYP2C8. The two polymorphic mutant sites of I264 and P404, located far from active site and substrate binding sites, significantly affect heme and/or substrate binding. This study indicated that two important nonsubstrate recognition site (SRS) residues of CYP2C8 are closely related to heme binding and/or substrate binding. This discovery could be valuable for explaining clinically individual differences in the metabolism of drugs and provides instructed information for individualized medication.
ACCESSION #
59398687

 

Related Articles

  • Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Leskelä, S; Jara, C; Leandro-García, L J; Martínez, A; García-Donas, J; Hernando, S; Hurtado, A; Vicario, J C C; Montero-Conde, C; Landa, I; López-Jiménez, E; Cascón, A; Milne, R L; Robledo, M; Rodríguez-Antona, C // Pharmacogenomics Journal;Apr2011, Vol. 11 Issue 2, p121 

    Neurotoxicity is one of the most relevant dose-limiting toxicities of the anticancer drug paclitaxel. It exhibits substantial interindividual variability of unknown molecular basis, and represents one of the major challenges for the improvement of paclitaxel therapy. The extensive variability in...

  • Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6. Yuan Ming Di; Vivian Deh-Wei Chow; Li-Ping Yang; Shu-Feng Zhou // Current Drug Metabolism;Sep2009, Vol. 10 Issue 7, p754 

    The CYP2A6 gene spans a region of approximately 6 kb pairs consisting of 9 exons and has been mapped to the long arm of chromosome 19 (between 19q12 and 19q13.2). The CYP2A6 protein has 494 amino acids and is an important hepatic Phase I enzyme that metabolizes ~3% of therapeutic drugs (n > 30;...

  • Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Bo Wang; Jing Wang; Shui-Qing Huang; Hai-Hao Su; Shu-Feng Zhou // Current Drug Metabolism;Sep2009, Vol. 10 Issue 7, p781 

    Human cytochrome P450 2C9 (CYP2C9) accounts for ~20% of total hepatic CYP content and metabolizes ~15% clinically used drugs including S-warfarin, tolbutamide, phenytoin, losartan, diclofenac, and celecoxib. To date, there are at least 33 variants of CYP2C9 (*1B through to *34) being identified....

  • Pharmacogenetics of Phase I and Phase II Drug Metabolism. Crettol, Severine; Petrovic, Nenad; Murray, Michael // Current Pharmaceutical Design;1/11/2010, Vol. 16 Issue 2, p204 

    Genetic variation in the receptors and other intracellular targets that mediate the pharmacodynamic effects of drugs can affect therapeutic outcomes. However, at present greater knowledge is available concerning the extent of gene variation in drug metabolizing enzymes that determine drug...

  • Comparison of Enzyme Kinetic Parameters Obtained In Vitro for Reactions Mediated by Human CYP2C Enzymes Including Major CYP2C9 Variants. Rokitta, D.; Fuhr, U. // Current Drug Metabolism;Feb2010, Vol. 11 Issue 2, p153 

    Cytochrome P450 (CYP) 2C enzymes contribute to the metabolism of about 30% of all drugs. Known polymorphisms of the respective enzymes and drug-drug interactions have a major impact on the efficacy and safety of some CYP2C substrate drugs. In vivo -- in vitro correlations including prediction of...

  • The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. Ya-Huei Liou; Chien-Ting Lin; Ying-Jye Wu; Wu, Lawrence // Journal of Human Genetics;Oct2006, Vol. 51 Issue 10, p857 

    Genetic polymorphisms of drug metabolizing enzymes, such as cytochromes P450 (CYPs), play major roles in the variations of drug responsiveness in human. The aim of this study is to identify the high prevalence (minor allele frequencies >1%) of the abnormal metabolite alleles of CYP2C9, CYP2C19,...

  • Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Rochat, Bertrand // Clinical Pharmacokinetics;2005, Vol. 44 Issue 4, p349 

    Although activity of cytochrome P450 isoenzymes (CYPs) plays a major role in the fate of anticancer agents in patients, there are relatively few clinical studies that evaluate drug metabolism with therapeutic outcome. Nevertheless, many clinical reports in various non-oncology fields have shown...

  • Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Tan, A R; Dowlati, A; Stein, M N; Jones, S F; Infante, J R; Bendell, J; Kane, M P; Levinson, K T; Suttle, A B; Burris III, H A // British Journal of Cancer;5/20/2014, Vol. 110 Issue 11, p2647 

    Background:We assessed the maximum tolerated regimen (MTR) and dose-limiting toxicities of pazopanib and lapatinib in combination with weekly paclitaxel, and the effect of pazopanib and lapatinib on paclitaxel pharmacokinetics.Methods:Patients received intravenous paclitaxel on days 1, 8, and 15...

  • Substrate binding to cytochromes P450. Isin, Emre M.; Guengerich, F. Peter // Analytical & Bioanalytical Chemistry;Nov2008, Vol. 392 Issue 6, p1019 

    P450s have attracted tremendous attention owing to not only their involvement in the metabolism of drug molecules and endogenous substrates but also the unusual nature of the reaction they catalyze, namely, the oxidation of unactivated C–H bonds. The binding of substrates to P450s, which...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics